Literature DB >> 32362317

New markers in Parkinson's disease.

Anastasia Bougea1.   

Abstract

Parkinson's disease (PD) is a chronic, debilitating neurodegenerative disorder characterized clinically by a variety of progressive motor and nonmotor symptoms. Currently, there is a dearth of diagnostic tools available to predict, diagnose or mitigate disease risk or progression, leading to a challenging dilemma within the healthcare management system. The search for a reliable biomarker for PD that reflects underlying pathology is a high priority in PD research. Currently, there is no reliable single biomarker predictive of risk for motor and cognitive decline, and there have been few longitudinal studies of temporal progression. A combination of multiple biomarkers might facilitate earlier diagnosis and more accurate prognosis in PD. In this review, we focus on the recent developments of serial biomarkers for PD from a variety of clinical, biochemical, genetic and neuroimaging perspectives.
© 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biomarkers; Cognitive decline; Longitudinal studies; Motor progression; Parkinson's disease (PD)

Mesh:

Substances:

Year:  2020        PMID: 32362317     DOI: 10.1016/bs.acc.2019.12.001

Source DB:  PubMed          Journal:  Adv Clin Chem        ISSN: 0065-2423            Impact factor:   5.394


  2 in total

1.  PBX1 attenuates 6-OHDA-induced oxidative stress and apoptosis and affects PINK1/PARKIN expression in dopaminergic neurons via FOXA1.

Authors:  Binglong Li; Di An; Shasha Zhu
Journal:  Cytotechnology       Date:  2022-01-24       Impact factor: 2.058

2.  A bibliometric analysis of neuroimaging biomarkers in Parkinson disease based on Web of Science.

Authors:  Xiao-Ling Li; Rui-Xue Gao; Qinhong Zhang; Ang Li; Li-Na Cai; Wei-Wei Zhao; Sheng-Lan Gao; Yang Wang; Jinhuan Yue
Journal:  Medicine (Baltimore)       Date:  2022-08-19       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.